Department of Neurology, University Medical Centre Utrecht Stroke Centre and Rudolf Magnus Institute of Neuroscience, UMC Utrecht, Utrecht, Netherlands.
Lancet Neurol. 2012 Mar;11(3):261-71. doi: 10.1016/S1474-4422(12)70005-4.
Diabetes and ischaemic stroke often arise together. People with diabetes have more than double the risk of ischaemic stroke after correction for other risk factors, relative to individuals without diabetes. Multifactorial treatment of risk factors for stroke-in particular, lifestyle factors, hypertension, and dyslipidaemia-will prevent a substantial number of these disabling strokes. Hyperglycaemia occurs in 30-40% of patients with acute ischaemic stroke, also in individuals without a known history of diabetes. Admission hyperglycaemia is associated with poor functional outcome, possibly through aggravation of ischaemic damage by disturbing recanalisation and increasing reperfusion injury. Uncertainty surrounds the question of whether glucose-lowering treatment for early stroke can improve clinical outcome. Achievement of normoglycaemia in the early stage of stroke can be difficult, and the possibility of hypoglycaemia remains a concern. Phase 3 studies of glucose-lowering therapy in acute ischaemic stroke are underway.
糖尿病和缺血性中风常常同时发生。在对其他风险因素进行校正后,糖尿病患者发生缺血性中风的风险比无糖尿病患者高两倍以上。针对中风风险因素的多因素治疗——尤其是生活方式因素、高血压和血脂异常——将预防大量这些致残性中风的发生。30%-40%的急性缺血性中风患者出现高血糖,即使在没有已知糖尿病病史的个体中也是如此。入院时的高血糖与不良的功能预后相关,可能是通过干扰再通和增加再灌注损伤而加重缺血性损伤。降低早期中风血糖水平能否改善临床预后的问题仍存在不确定性。在中风的早期阶段实现正常血糖水平可能具有挑战性,并且发生低血糖的可能性仍然令人担忧。急性缺血性中风中降低血糖治疗的 3 期研究正在进行中。